Repligen Corporation (RGEN) Sets All-Time High at $47.67 on Jun, 29

June 29, 2018 - By Lena Young

Repligen Corporation (NASDAQ:RGEN) Corporate Logo

Big Money Sentiment increased to 1.39 in 2018 Q1. It has change of 0.13, from 2017Q4’s 1.26. The ratio is positive due to Repligen Corporation positioning: 13 sold and 46 reduced. 19 funds bought holdings and 63 increased holdings. Investors holded 35.19 million in 2017Q4 but now own 35.98 million shares or 2.25% more.
California Pub Employees Retirement Sys accumulated 125,214 shs or 0.01% of the stock. Rice Hall James And Associates Limited Liability Corporation holds 0.07% or 52,151 shs in its capital. Daiwa Securities Group Inc holds 241 shs. Eaton Vance Mngmt owns 12,780 shs. Citigroup has invested 0% in Repligen Corporation (NASDAQ:RGEN). Wells Fargo & Mn accumulated 738,506 shs. 190,417 were reported by Schwab Charles Inv Management. Clarivest Asset Mgmt Limited Liability holds 0.05% or 84,422 shs. Barclays Public has 13,915 shs for 0% of their capital. Pdt Prns Ltd Liability Co holds 0.06% or 48,220 shs in its capital. Morgan Stanley holds 91,271 shs. Price T Rowe Assoc Md has 451,553 shs. Prudential Fin invested 0% of its capital in Repligen Corporation (NASDAQ:RGEN). Bartlett And Ltd Company stated it has 0% of its capital in Repligen Corporation (NASDAQ:RGEN). Ls Investment Advisors Ltd Liability Com invested 0.01% in Repligen Corporation (NASDAQ:RGEN).

Repligen Corporation had 8 selling transactions and 0 buys since January 22, 2018. This’s net activity of $13.05 million. 26,500 shs were sold by BARTHELEMY NICOLAS, worth $1.07 million on Wednesday, May 9. Another trade for 8,970 shs valued at $322,445 was made by Hunt Anthony on Monday, January 22. On Friday, May 11 Shares for $835,936 were sold by DAWES KAREN A. The insider EDDLEMAN ROY T sold $5.00M.

By reaching $47.67 share price all time high was [achieved] by Repligen Corporation (NASDAQ:RGEN). Barchart.com announced it. The company has $2.08 billion MC. $124.98M more could be NASDAQ:RGEN valuation at $50.53 share price.

Ticker’s shares touched $47.67 during the last trading session after 1.87% change.Currently Repligen Corporation is uptrending after 11.84% change in last June 29, 2017. RGEN has 155,508 shares volume. The stock underperformed the S&P 500 by 0.73%.

Earnings report for Repligen Corporation (NASDAQ:RGEN) is expected on August, 2., according to RTT. Last year’s earnings per share was $0.2, while now analysts expect change of 5.00 % down from current $0.19 earnings per share. If the current earnings per share of $0.19 is accurate, RGEN’s profit could hit $8.30 million. After $0.17 earnings per share was revealed previous quarter, analysts now see EPS growth of 11.76 % for Repligen Corporation.

A couple more Repligen Corporation (NASDAQ:RGEN) news were published by: Nasdaq.com which released on June 27, 2018 “Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity …”, also Nasdaq.com on June 28, 2018 published “Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading” on June 27, 2018. Globenewswire.com has article titled “Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton …”.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The firm is worth $2.08 billion. It makes various forms of Protein A, a critical component used to purify antibody drugs.The P/E ratio is 66.22. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.